To include your compound in the COVID-19 Resource Center, submit it here.

AsclepiX aims for basket of retinal indications with $35M series A

Perceptive Xontogeny Venture Fund invested alongside Perceptive Advisors’ master life sciences fund

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology.

Spun out of The Johns Hopkins University, the Baltimore start-up believes the round will be enough to generate safety and efficacy data for AXT107, which has a dual mechanism that targets VEGF and Tie2 to treat diabetic macular edema,

Read the full 699 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE